Stockreport

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights [Yahoo! Finance]

Atai Beckley N.V - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line [Read more]